<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680107</article-id><article-id pub-id-type="doi">10.3390/v16121825</article-id><article-id pub-id-type="publisher-id">viruses-16-01825</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Special Issue &#x0201c;Host Targeted Therapeutics Against Virus Infections&#x0201d;</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7372-7089</contrib-id><name><surname>Pleschka</surname><given-names>Stephan</given-names></name><xref rid="af1-viruses-16-01825" ref-type="aff">1</xref><xref rid="af2-viruses-16-01825" ref-type="aff">2</xref></contrib></contrib-group><aff id="af1-viruses-16-01825"><label>1</label>Institute of Medical Virology, Justus Liebig University Giessen, 35392 Giessen, Germany; <email>stephan.pleschka@viro.med.uni-giessen.de</email></aff><aff id="af2-viruses-16-01825"><label>2</label>German Center for Infection Research (DZIF), Partner Site Giessen, 35392 Giessen, Germany</aff><pub-date pub-type="epub"><day>25</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1825</elocation-id><history><date date-type="received"><day>13</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the author.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01825"><title>1. Introduction</title><p>The COVID-19 pandemic, along with the emergence and sustained transmission of highly pathogenic avian influenza viruses (H5N1) in U.S. dairy cattle, as well as the recurrent appearance of other viruses with high public health impact, underscores the critical need for effective antiviral treatments and therapies. Although vaccines remain the cornerstone of preventive strategies when available, targeted treatments for infected individuals are frequently lacking. Given that viral replication depends on host cellular machinery, there is growing interest in host-directed antiviral strategies, known as host-targeted antivirals (HTAs). HTAs hold the potential not only to combat a single virus strain but also to exhibit broad-spectrum antiviral activity across multiple members within and even beyond a virus family. This host-targeted approach is less prone to resistance development, as it interferes with host cellular factors rather than viral components encoded by the virus itself. Moreover, HTAs can be pre-manufactured or rapidly deployed in response to outbreaks. Once controversial, the concept of targeting host cellular functions for antiviral therapy has gained substantial acceptance over the past two decades. The five research articles and two reviews featured in this Special Issue present novel findings in the realm of host-targeted antiviral strategies and therapeutic interventions.</p></sec><sec id="sec2-viruses-16-01825"><title>2. Contributions</title><p>In the first publication of this Special Issue, Jonatan C. S. de Carvalho et al. [<xref rid="B1-viruses-16-01825" ref-type="bibr">1</xref>] (and citations therein) provide evidence that glucocorticoids (GCs), known primarily for their role in suppressing pro-inflammatory cytokines and lipid mediators, may offer protective pharmacological benefits against COVID-19-related inflammation. The study suggests that GCs could reduce levels of platelet-activating factor (PAF), a key lipid mediator implicated in COVID-19 pathogenesis, while simultaneously increasing lipid mediators from the endocannabinoid (eCB) group, which play a crucial role in modulating an effective innate immune response during inflammation. Based on these findings, the authors propose potential therapeutic strategies targeting different phases of lipid mediator metabolism to modulate immune responses for COVID-19 treatment.</p><p>Charlotte Foret-Lucas et al. [<xref rid="B2-viruses-16-01825" ref-type="bibr">2</xref>] (and citations therein) demonstrate that inhibiting EPAC1 with the specific pharmacological agent AM-001 effectively suppresses early stages of the SARS-CoV-2 replication cycle. The authors report a concentration-dependent reduction in the release of infectious SARS-CoV-2 and H1N1 influenza A virus particles (measured by TCID50 assay), as well as a decrease in SARS-CoV-2 viral RNA release (quantified by RT-qPCR). Notably, AM-001 treatment showed no virucidal activity and did not significantly affect cellular viability, indicating a targeted mechanism of action. These findings suggest that EPAC1 inhibition may serve as a promising therapeutic strategy against selected viral infections.</p><p>In their study, Tosin Oladipo Afowowe et al. [<xref rid="B3-viruses-16-01825" ref-type="bibr">3</xref>] (and citations therein) identified topoisomerase II as a novel antiviral target for panarenaviral diseases. Utilizing modified minigenome (MG) systems for Lassa virus (LASV) and Junin virus (JUNV), which cause Lassa fever and hemorrhagic fever with mortality rates of 15&#x02013;30% and up to 30% [<xref rid="B4-viruses-16-01825" ref-type="bibr">4</xref>], respectively, the authors screened both an FDA-approved compound library and additional agents. They found that topoisomerase II inhibitors suppressed LASV and JUNV MG activity and significantly limited JUNV infection. Additionally, siRNA knockdown of topoisomerase II&#x003b1; and II&#x003b2; reduced JUNV replication, suggesting that topoisomerase II could serve as a molecular target for broad-spectrum panarenaviral inhibitors.</p><p>Wiebke Obermann et al. [<xref rid="B5-viruses-16-01825" ref-type="bibr">5</xref>] (and citations therein) investigated rocaglates, such as silvestrol, as antiviral agents. These plant-derived compounds inhibit viral protein synthesis across various RNA viruses by clamping 5&#x02032;-UTRs of viral mRNAs to the RNA helicase eIF4A, thus blocking initiation of translation [<xref rid="B6-viruses-16-01825" ref-type="bibr">6</xref>]. Using reporter systems with 5&#x02032;-UTRs from human coronavirus 229E (HCoV-229E), MERS-CoV, and SARS-CoV-2, the authors found that silvestrol, along with synthetic rocaglates CR-1-31-B and zotatifin, exerted dose-dependent antiviral effects, with distinct profiles in cytotoxicity and efficacy. Notably, HCoV-229E showed no resistance to rocaglates under serial passaging, highlighting their potential as broad-spectrum antivirals effective at nanomolar concentrations.</p><p>Beatriz Sierra et al. [<xref rid="B7-viruses-16-01825" ref-type="bibr">7</xref>] (and citations therein) utilized multi-tissue transcriptomics for in silico-guided drug selection, followed by functional assessment against Dengue fever. By analyzing transcriptomic data from liver, spleen, and blood samples of both infected and non-infected deceased individuals, the study identified common host mechanisms that could be targeted by known compounds to mitigate severe Dengue virus infection. The authors propose that these identified compounds represent promising candidates for further functional evaluation and clinical trials.</p><p>In their review, Jens Kleinehr et al. [<xref rid="B8-viruses-16-01825" ref-type="bibr">8</xref>] examine metabolic alterations induced by common respiratory viruses and explore their potential as novel antiviral targets. Given their reliance on host cells, respiratory viruses&#x02014;responsible for frequent human lung infections&#x02014;significantly modify cellular functions to favor viral replication, notably altering metabolic pathways. The authors provide a comprehensive summary of current knowledge on metabolic pathway modifications driven by acute respiratory syncytial virus, rhinovirus, influenza virus, parainfluenza virus, coronavirus, and adenovirus, identifying potential therapeutic targets and compounds for antiviral strategies.</p><p>In their review, Ralf Kircheis et al. [<xref rid="B9-viruses-16-01825" ref-type="bibr">9</xref>] examine the disparity in COVID-19 mortality between heavily impacted regions such as Europe and the Americas and regions such as Africa, which reported lower infection and death rates by 2021. Analyzing this &#x0201c;African paradox&#x0201d;, the authors explore correlations among immunological and genetic factors, pre-existing immune status, cytokine induction patterns, and epidemiological factors. They propose that a young population with lower comorbidity rates, high prevalence of helminth and malaria infections, and widespread use of anti-helminth and anti-malaria drugs with anti-inflammatory properties may contribute to the observed outcomes, emphasizing the role of the NF-&#x003ba;B pathway. The authors suggest that understanding these epidemiological and immunological correlations could guide the development of COVID-19 therapies, including the repurposing of existing NF-&#x003ba;B inhibitors.</p></sec><sec sec-type="conclusions" id="sec3-viruses-16-01825"><title>3. Conclusions and Outlook</title><p>This Special Issue showcases diverse antiviral strategies targeting host factors and mechanisms, underscoring the significant therapeutic potential of HTAs in combating a range of viral threats. Key approaches include the modulation of pro-inflammatory factors and pathways, disruption of cellular factors and mechanisms essential for viral gene expression and genome replication, and targeting of metabolic pathways crucial for specific viruses. Collectively, these strategies illustrate an expanding array of potential tactics that, with advancing methodologies, can be further refined to offer effective options for improved viral disease control in the future.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The author declares no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01825"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Carvalho</surname><given-names>J.C.S.</given-names></name>
<name><surname>da Silva-Neto</surname><given-names>P.V.</given-names></name>
<name><surname>Toro</surname><given-names>D.M.</given-names></name>
<name><surname>Fuzo</surname><given-names>C.A.</given-names></name>
<name><surname>Nardini</surname><given-names>V.</given-names></name>
<name><surname>Pimentel</surname><given-names>V.E.</given-names></name>
<name><surname>P&#x000e9;rez</surname><given-names>M.M.</given-names></name>
<name><surname>Fraga-Silva</surname><given-names>T.F.C.</given-names></name>
<name><surname>Oliveira</surname><given-names>C.N.S.</given-names></name>
<name><surname>Degiovani</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group><article-title>The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>573</elocation-id><pub-id pub-id-type="doi">10.3390/v15020573</pub-id><pub-id pub-id-type="pmid">36851787</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01825"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foret-Lucas</surname><given-names>C.</given-names></name>
<name><surname>Figueroa</surname><given-names>T.</given-names></name>
<name><surname>Bertin</surname><given-names>A.</given-names></name>
<name><surname>Bessi&#x000e8;re</surname><given-names>P.</given-names></name>
<name><surname>Lucas</surname><given-names>A.</given-names></name>
<name><surname>Bergonnier</surname><given-names>D.</given-names></name>
<name><surname>Wasniewski</surname><given-names>M.</given-names></name>
<name><surname>Servat</surname><given-names>A.</given-names></name>
<name><surname>Tessier</surname><given-names>A.</given-names></name>
<name><surname>Lezoualc&#x02019;h</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>EPAC1 Pharmacological Inhibition with AM-001 Prevents SARS-CoV-2 and Influenza A Virus Replication in Cells</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>319</elocation-id><pub-id pub-id-type="doi">10.3390/v15020319</pub-id><pub-id pub-id-type="pmid">36851533</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01825"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Afowowe</surname><given-names>T.O.</given-names></name>
<name><surname>Sakurai</surname><given-names>Y.</given-names></name>
<name><surname>Urata</surname><given-names>S.</given-names></name>
<name><surname>Zadeh</surname><given-names>V.R.</given-names></name>
<name><surname>Yasuda</surname><given-names>J.</given-names></name>
</person-group><article-title>Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>105</elocation-id><pub-id pub-id-type="doi">10.3390/v15010105</pub-id><pub-id pub-id-type="pmid">36680145</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01825"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>H.</given-names></name>
<name><surname>Cong</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Ji</surname><given-names>W.</given-names></name>
<name><surname>Xin</surname><given-names>Y.</given-names></name>
<name><surname>Qian</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Rao</surname><given-names>Z.</given-names></name>
</person-group><article-title>Structural basis for recognition and regulation of arenavirus polymerase L by Z protein</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>4134</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24458-1</pub-id><pub-id pub-id-type="pmid">34226547</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01825"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Obermann</surname><given-names>W.</given-names></name>
<name><surname>Friedrich</surname><given-names>A.</given-names></name>
<name><surname>Madhugiri</surname><given-names>R.</given-names></name>
<name><surname>Klemm</surname><given-names>P.</given-names></name>
<name><surname>Mengel</surname><given-names>J.P.</given-names></name>
<name><surname>Hain</surname><given-names>T.</given-names></name>
<name><surname>Pleschka</surname><given-names>S.</given-names></name>
<name><surname>Wendel</surname><given-names>H.-G.</given-names></name>
<name><surname>Hartmann</surname><given-names>R.K.</given-names></name>
<name><surname>Schiffmann</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>519</elocation-id><pub-id pub-id-type="doi">10.3390/v14030519</pub-id><pub-id pub-id-type="pmid">35336926</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01825"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hinnebusch</surname><given-names>A.G.</given-names></name>
<name><surname>Ivanov</surname><given-names>I.P.</given-names></name>
<name><surname>Sonenberg</surname><given-names>N.</given-names></name>
</person-group><article-title>Translational control by 5&#x02032;-untranslated regions of eukaryotic mRNAs</article-title><source>Science</source><year>2016</year><volume>352</volume><fpage>1413</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1126/science.aad9868</pub-id><pub-id pub-id-type="pmid">27313038</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01825"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sierra</surname><given-names>B.</given-names></name>
<name><surname>Magalh&#x000e3;es</surname><given-names>A.C.</given-names></name>
<name><surname>Soares</surname><given-names>D.</given-names></name>
<name><surname>Cavadas</surname><given-names>B.</given-names></name>
<name><surname>Perez</surname><given-names>A.B.</given-names></name>
<name><surname>Alvarez</surname><given-names>M.</given-names></name>
<name><surname>Aguirre</surname><given-names>E.</given-names></name>
<name><surname>Bracho</surname><given-names>C.</given-names></name>
<name><surname>Pereira</surname><given-names>L.</given-names></name>
<name><surname>Guzman</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Multi-Tissue Transcriptomic-Informed In Silico Investigation of Drugs for the Treatment of Dengue Fever Disease</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1540</elocation-id><pub-id pub-id-type="doi">10.3390/v13081540</pub-id><pub-id pub-id-type="pmid">34452405</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01825"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleinehr</surname><given-names>J.</given-names></name>
<name><surname>Wilden</surname><given-names>J.J.</given-names></name>
<name><surname>Boergeling</surname><given-names>Y.</given-names></name>
<name><surname>Ludwig</surname><given-names>S.</given-names></name>
<name><surname>Hrincius</surname><given-names>E.R.</given-names></name>
</person-group><article-title>Metabolic Modifications by Common Respiratory Viruses and Their Potential as New Antiviral Targets</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>2068</elocation-id><pub-id pub-id-type="doi">10.3390/v13102068</pub-id><pub-id pub-id-type="pmid">34696497</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01825"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kircheis</surname><given-names>R.</given-names></name>
<name><surname>Schuster</surname><given-names>M.</given-names></name>
<name><surname>Planz</surname><given-names>O.</given-names></name>
</person-group><article-title>COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF-&#x003ba;B Pathway</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1887</elocation-id><pub-id pub-id-type="doi">10.3390/v13091887</pub-id><pub-id pub-id-type="pmid">34578468</pub-id>
</element-citation></ref></ref-list></back></article>